Published in Endocrinology on November 22, 2006
Novel transcriptional profile in wrist muscles from cerebral palsy patients. BMC Med Genomics (2009) 1.01
pRb-dependent cyclin D3 protein stabilization is required for myogenic differentiation. Mol Cell Biol (2007) 0.94
Endogenous hydrogen peroxide regulates glutathione redox via nuclear factor erythroid 2-related factor 2 downstream of phosphatidylinositol 3-kinase during muscle differentiation. Am J Pathol (2008) 0.92
Protein kinase D2 is an essential regulator of murine myoblast differentiation. PLoS One (2011) 0.81
eEF1A phosphorylation in the nucleus of insulin-stimulated C2C12 myoblasts: Ser⁵³ is a novel substrate for protein kinase C βI. Mol Cell Proteomics (2010) 0.81
Phosphoinositide-specific phospholipase C β 1b (PI-PLCβ1b) interactome: affinity purification-mass spectrometry analysis of PI-PLCβ1b with nuclear protein. Mol Cell Proteomics (2013) 0.79
IPMK and β-catenin mediate PLC-β1-dependent signaling in myogenic differentiation. Oncotarget (2016) 0.75
Roles of the Raf/MEK/ERK pathway in cell growth, malignant transformation and drug resistance. Biochim Biophys Acta (2006) 7.33
The A2B adenosine receptor protects against inflammation and excessive vascular adhesion. J Clin Invest (2006) 3.49
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR inhibitors: rationale and importance to inhibiting these pathways in human health. Oncotarget (2011) 3.43
Multiple roles of phosphoinositide-specific phospholipase C isozymes. BMB Rep (2008) 2.90
Roles of the Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR pathways in controlling growth and sensitivity to therapy-implications for cancer and aging. Aging (Albany NY) (2011) 2.72
The reno-vascular A2B adenosine receptor protects the kidney from ischemia. PLoS Med (2008) 2.43
Requirement of inositol pyrophosphates for full exocytotic capacity in pancreatic beta cells. Science (2007) 2.36
Deletion of Cavin/PTRF causes global loss of caveolae, dyslipidemia, and glucose intolerance. Cell Metab (2008) 2.28
Concern Equilibrative nucleoside transporter 1 (ENT1) regulates postischemic blood flow during acute kidney injury in mice. J Clin Invest (2012) 2.23
Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascade inhibitors: how mutations can result in therapy resistance and how to overcome resistance. Oncotarget (2012) 1.96
A2B adenosine receptor promotes mesenchymal stem cell differentiation to osteoblasts and bone formation in vivo. J Biol Chem (2012) 1.88
Mutations and deregulation of Ras/Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR cascades which alter therapy response. Oncotarget (2012) 1.85
Mechanism of Aurora-B degradation and its dependency on intact KEN and A-boxes: identification of an aneuploidy-promoting property. Mol Cell Biol (2005) 1.67
Upregulation of Nox4 in the aging vasculature and its association with smooth muscle cell polyploidy. Cell Cycle (2009) 1.63
GSK-3 as potential target for therapeutic intervention in cancer. Oncotarget (2014) 1.56
NK cells and cancer. J Immunol (2007) 1.56
Phosphoinositide-phospholipase C beta1 mono-allelic deletion is associated with myelodysplastic syndromes evolution into acute myeloid leukemia. J Clin Oncol (2008) 1.56
A2B adenosine receptor gene deletion attenuates murine colitis. Gastroenterology (2008) 1.49
Activity of the novel dual phosphatidylinositol 3-kinase/mammalian target of rapamycin inhibitor NVP-BEZ235 against T-cell acute lymphoblastic leukemia. Cancer Res (2010) 1.46
The nuclear phosphoinositide 3-kinase/AKT pathway: a new second messenger system. Biochim Biophys Acta (2002) 1.42
Akt as a therapeutic target in cancer. Expert Opin Ther Targets (2008) 1.41
Animal models for the study of adenosine receptor function. J Cell Physiol (2005) 1.41
Therapeutic resistance resulting from mutations in Raf/MEK/ERK and PI3K/PTEN/Akt/mTOR signaling pathways. J Cell Physiol (2011) 1.40
The A2b adenosine receptor protects against vascular injury. Proc Natl Acad Sci U S A (2008) 1.39
CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer (2005) 1.38
AML1/RUNX1 increases during G1 to S cell cycle progression independent of cytokine-dependent phosphorylation and induces cyclin D3 gene expression. J Biol Chem (2004) 1.31
Dual inhibition of class IA phosphatidylinositol 3-kinase and mammalian target of rapamycin as a new therapeutic option for T-cell acute lymphoblastic leukemia. Cancer Res (2009) 1.29
Targeting the Raf/MEK/ERK pathway with small-molecule inhibitors. Curr Opin Investig Drugs (2008) 1.25
Targeting prostate cancer based on signal transduction and cell cycle pathways. Cell Cycle (2008) 1.25
The emerging multiple roles of nuclear Akt. Biochim Biophys Acta (2012) 1.25
Deregulated Aurora-B induced tetraploidy promotes tumorigenesis. FASEB J (2009) 1.23
A combination of temsirolimus, an allosteric mTOR inhibitor, with clofarabine as a new therapeutic option for patients with acute myeloid leukemia. Oncotarget (2012) 1.23
Intranuclear 3'-phosphoinositide metabolism and Akt signaling: new mechanisms for tumorigenesis and protection against apoptosis? Cell Signal (2006) 1.22
Inositol pyrophosphates: structure, enzymology and function. Cell Mol Life Sci (2009) 1.21
The Raf/MEK/ERK pathway can govern drug resistance, apoptosis and sensitivity to targeted therapy. Cell Cycle (2010) 1.18
Inhibition of connective tissue growth factor (CTGF/CCN2) expression decreases the survival and myogenic differentiation of human rhabdomyosarcoma cells. Cancer Res (2004) 1.17
Involvement of Akt and mTOR in chemotherapeutic- and hormonal-based drug resistance and response to radiation in breast cancer cells. Cell Cycle (2011) 1.17
Involvement of Akt-1 and mTOR in sensitivity of breast cancer to targeted therapy. Oncotarget (2011) 1.16
Emerging MEK inhibitors. Expert Opin Emerg Drugs (2010) 1.16
Activity of the selective IκB kinase inhibitor BMS-345541 against T-cell acute lymphoblastic leukemia: involvement of FOXO3a. Cell Cycle (2012) 1.11
Lysyl oxidase propeptide inhibits smooth muscle cell signaling and proliferation. Biochem Biophys Res Commun (2007) 1.10
Synergistic induction of apoptosis in human leukemia T cells by the Akt inhibitor perifosine and etoposide through activation of intrinsic and Fas-mediated extrinsic cell death pathways. Mol Cancer Ther (2006) 1.10
TNF-alpha upregulates the A2B adenosine receptor gene: The role of NAD(P)H oxidase 4. Biochem Biophys Res Commun (2008) 1.09
Links between insulin resistance, adenosine A2B receptors, and inflammatory markers in mice and humans. Diabetes (2011) 1.06
The protein kinase Akt/PKB regulates both prelamin A degradation and Lmna gene expression. FASEB J (2013) 1.06
TLR stimulation initiates a CD39-based autoregulatory mechanism that limits macrophage inflammatory responses. Blood (2013) 1.06
Lysyl oxidase oxidizes cell membrane proteins and enhances the chemotactic response of vascular smooth muscle cells. J Biol Chem (2008) 1.06
Advances in targeting signal transduction pathways. Oncotarget (2012) 1.06
Vascular smooth muscle cell polyploidization involves changes in chromosome passenger proteins and an endomitotic cell cycle. Exp Cell Res (2005) 1.05
Synergistic proapoptotic activity of recombinant TRAIL plus the Akt inhibitor Perifosine in acute myelogenous leukemia cells. Cancer Res (2008) 1.04
BclxL overexpression in megakaryocytes leads to impaired platelet fragmentation. Blood (2002) 1.04
Constitutive traffic of melanocortin-4 receptor in Neuro2A cells and immortalized hypothalamic neurons. J Biol Chem (2006) 1.04
Anticancer agents sensitize osteosarcoma cells to TNF-related apoptosis-inducing ligand downmodulating IAP family proteins. Int J Oncol (2006) 1.04
Temsirolimus, an mTOR inhibitor, in combination with lower-dose clofarabine as salvage therapy for older patients with acute myeloid leukaemia: results of a phase II GIMEMA study (AML-1107). Br J Haematol (2011) 1.04
The AKT inhibitor MK-2206 is cytotoxic in hepatocarcinoma cells displaying hyperphosphorylated AKT-1 and synergizes with conventional chemotherapy. Oncotarget (2013) 1.03
Activation of the macrophage A2b adenosine receptor regulates tumor necrosis factor-alpha levels following vascular injury. Exp Hematol (2009) 1.03
Crosstalk between the equilibrative nucleoside transporter ENT2 and alveolar Adora2b adenosine receptors dampens acute lung injury. FASEB J (2013) 1.02
Lamin A Ser404 is a nuclear target of Akt phosphorylation in C2C12 cells. J Proteome Res (2008) 1.02
Threonine 308 phosphorylated form of Akt translocates to the nucleus of PC12 cells under nerve growth factor stimulation and associates with the nuclear matrix protein nucleolin. J Cell Physiol (2003) 1.02
Fundamental differences in endoreplication in mammals and Drosophila revealed by analysis of endocycling and endomitotic cells. Proc Natl Acad Sci U S A (2013) 1.02
The Akt/mammalian target of rapamycin signal transduction pathway is activated in high-risk myelodysplastic syndromes and influences cell survival and proliferation. Cancer Res (2007) 1.02
Diacylglycerol kinase-theta is localized in the speckle domains of the nucleus. Exp Cell Res (2003) 1.01
The A2b adenosine receptor modulates glucose homeostasis and obesity. PLoS One (2012) 1.01
Targeting the RAF/MEK/ERK, PI3K/AKT and p53 pathways in hematopoietic drug resistance. Adv Enzyme Regul (2007) 1.01
Timing and expression level of protein kinase C epsilon regulate the megakaryocytic differentiation of human CD34 cells. Stem Cells (2007) 1.00
Properties of ets-1 binding to chromatin and its effect on platelet factor 4 gene expression. Mol Cell Biol (2004) 0.99
Adenosine 2B receptors (A(2B)AR) on enteric neurons regulate murine distal colonic motility. FASEB J (2009) 0.98
A2b adenosine receptor regulates hyperlipidemia and atherosclerosis. Circulation (2011) 0.97
Targeting the cancer initiating cell: the ultimate target for cancer therapy. Curr Pharm Des (2012) 0.96
Signaling by the Mpl receptor involves IKK and NF-kappaB. J Cell Biochem (2002) 0.96
Tetraploidy/aneuploidy and stem cells in cancer promotion: The role of chromosome passenger proteins. J Cell Physiol (2006) 0.96
Conditional overexpression of transgenes in megakaryocytes and platelets in vivo. Blood (2005) 0.96
Preclinical testing of the Akt inhibitor triciribine in T-cell acute lymphoblastic leukemia. J Cell Physiol (2011) 0.96
Ankrd2/ARPP is a novel Akt2 specific substrate and regulates myogenic differentiation upon cellular exposure to H(2)O(2). Mol Biol Cell (2011) 0.95
Direct visualization of the endomitotic cell cycle in living megakaryocytes: differential patterns in low and high ploidy cells. Cell Cycle (2008) 0.95
A(3) adenosine receptor deficiency does not influence atherogenesis. J Cell Biochem (2004) 0.95
New roles for cyclin E in megakaryocytic polyploidization. J Biol Chem (2010) 0.95
Caspase-dependent cleavage of 170-kDa P-glycoprotein during apoptosis of human T-lymphoblastoid CEM cells. J Cell Physiol (2006) 0.95
Harnessing the PI3K/Akt/mTOR pathway in T-cell acute lymphoblastic leukemia: eliminating activity by targeting at different levels. Oncotarget (2012) 0.94